In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Kurt Huber
Kurt Huber Kurt Huber

Wilhelminen Hospital, Vienna (Austria)

Specialities : Interventional Cardiology , Acute Cardiac Care, Basic Science, Risk Factors and Prevention

Kurt Huber, MD, FESC, FACC, FAHA, is director of the Department of Cardiology and intensive Care Medicine at the Wilhelminenhospital and Dean of Research and Professor for Acute and Interventional Cardiology at the Sigmund Freud University, Medical School, Vienna, Austria. He is an interventional cardiologist with over 35 years of experience. His main research interest covers basic research (mechanisms of thrombus formation and dissolution) as well as clinical research (acute coronary syndromes, organization of STEMI networks, antithrombotic therapy in CV diseases). He has performed over 100 international clinical trials as national coordinator and steering committee member, has published over 800 peer reviewed papers to date, his Hirsh factor is 84 (Thomson Reuters), his life IF > 4000, he has organized > 200 national and international conferences, and he has been listed annually since 2015 among the top 0,1% of the most cited researchers globally in Clinical Medicine.

73 presentations from this speaker

ACVC Pills on atrial fibrillation in acute heart failure.

Event : Acute Cardiovascular Care 2021

  • Session : ACVC Pills on Atrial Fibrillation in Acute Heart Failure
  • Speaker : F Guerra (Ancona,IT), K Huber (Vienna,AT)

COVID-19: implications for prehospital, emergency and hospital care in patients with acute coronary syndromes – the European perspective.

Event : Acute Cardiovascular Care 2021

  • Session : And then, there was only COVID-19, a transatlantic view on a common enemy.
  • Speaker : K Huber (Vienna,AT)

P2Y12-inhibitors in NSTEMI - old and new guidelines.

Event : Webinar 2021

  • Session : ACVC Webinars 2021
  • Speaker : K Huber (Vienna,AT), S James (Uppsala,SE), SD Kristensen (Aarhus N,DK)

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.

Event : Acute Cardiovascular Care 2021

  • Session : Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?
  • Speaker : K Huber (Vienna,AT)

How to individualise DAPT duration after an acute coronary syndrome.

Event : Webinar 2020

  • Session : ACVC Webinars 2020
  • Speaker : F Costa (Messina,IT), K Huber (Vienna,AT), S Leonardi (Pavia,IT)

Lower LDL-C is better, but is earlier better after ACS.

Event : Webinar 2020

  • Session : ACVC Webinars 2020
  • Speaker : K Huber (Vienna,AT), M Claeys (Edegem /Antwerpen,BE), G Montalescot (Paris,FR)

Q&A.

Event : ESC Congress 2020

  • Session : Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
  • Speaker : K Huber (Vienna,AT), D Capodanno (Catania,IT), S James (Uppsala,SE), R Mehran (New York,US)
  • Organised by Radcliffe Cardiology, supported by AstraZeneca in the form of an educational grant

Summary and close.

Event : ESC Congress 2020

  • Session : Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
  • Speaker : K Huber (Vienna,AT)
  • Organised by Radcliffe Cardiology, supported by AstraZeneca in the form of an educational grant

The trial of the trials: AUGUSTUS vs ENTRUST AF PCI: from trial design to clinical implications.

Event : Webinar 2020

  • Session : ACVC Webinars 2020
  • Speaker : S Leonardi (Pavia,IT), P Vranckx (Hasselt,BE), K Huber (Vienna,AT)

Triple therapy: still an option?

Event : ESC Congress 2020

  • Session : Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting
  • Speaker : K Huber (Vienna,AT)

Welcome.

Event : ESC Congress 2020

  • Session : Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
  • Speaker : K Huber (Vienna,AT)
  • Organised by Radcliffe Cardiology, supported by AstraZeneca in the form of an educational grant

Balancing bleeding and ischemic risk in acute coronary syndromes treatment.

Event : ESC Congress 2019

  • Session : Antithrombotic therapy in patients with acute coronary syndromes
  • Speaker : K Huber (Vienna,AT)
  • Joint with the Chinese Society of Cardiology

Case 1: a patient anticoagulated for atrial fibrillation admitted with NSTEMI.

Event : ESC Congress 2019

  • Session : Meet the Experts - Atrial fibrillation in patients with acute coronary syndromes: how annoying!
  • Speaker : K Huber (Vienna,AT)

Case 3: Diagnosis and prevention of stroke.

Event : Acute Cardiovascular Care 2019

  • Session : Acute complications in patients undergoing transcatheter aortic valve replacement
  • Speaker : K Huber (Vienna,AT)

Dual Anti Platelet Therapy in 2019 - current recommendations.

Event : Webinar 2019

  • Session : ESC Webinars 2019
  • Speaker : K Huber (Vienna,AT), MR Thomas (Birmingham,GB)

Dual therapy for all ACS patients with atrial fibrillation receiving coronary stents - Moderated discussion.

Event : Acute Cardiovascular Care 2019

  • Session : Dual or triple antithrombotic therapy?
  • Speaker : K Huber (Vienna,AT)

Introduction to the session.

Event : Acute Cardiovascular Care 2019

  • Session : Optimal primary PCI: strategies and patient selection
  • Speaker : K Huber (Vienna,AT)

Non-coronary challenges in acute cardiovascular care.

Event : Acute Cardiovascular Care 2019

  • Session : Highlights from Acute Cardiovascular Care 2019 & Closing Ceremony
  • Speaker : K Huber (Vienna,AT)

Panel discussion - Safety implications of anticoagulation therapy in acute cardiovascular care.

Event : Acute Cardiovascular Care 2019

  • Session : Safety implications of anticoagulation therapy in acute cardiovascular care
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Positioning of the topic - DAT for all ACS patients with atrial fibrillation receiving coronary stents

Event : Acute Cardiovascular Care 2019

  • Session : Dual or triple antithrombotic therapy?
  • Speaker : K Huber (Vienna,AT)

Summary and conclusions - Safety implications of anticoagulation therapy in acute cardiovascular care.

Event : Acute Cardiovascular Care 2019

  • Session : Safety implications of anticoagulation therapy in acute cardiovascular care
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Welcome and introduction - Safety implications of anticoagulation therapy in acute cardiovascular care.

Event : Acute Cardiovascular Care 2019

  • Session : Safety implications of anticoagulation therapy in acute cardiovascular care
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

What are the implications of GLOBAL LEADERS for clinical practice?

Event : Acute Cardiovascular Care 2019

  • Session : The trial of the trial: Assessing GLOBAL LEADERS innovations, limitations and implications for clinical practice
  • Speaker : K Huber (Vienna,AT)

Anticoagulation and antiplatelets: when and how?

Event : Acute Cardiovascular Care 2018

  • Session : Pre-hospital ACS: diagnosis and treatments
  • Speaker : K Huber (Vienna,AT)

Antiplatelets – Role of dual or triple therapy

Event : Heart Failure 2018

  • Session : Antithrombotics in heart failure
  • Speaker : K Huber (Vienna,AT)

Atrial fibrillation, acute coronary syndrome and coronary intervention: new concepts and controversies.

Event : ESC Congress 2018

  • Session : Atrial fibrillation in the context of acute coronary syndromes and coronary intervention: what should we do?
  • Speaker : K Huber (Vienna,AT)

Challenges in managing AF patients undergoing cardiovascular interventions.

Event : Acute Cardiovascular Care 2018

  • Session : Cardiovascular interventions in patients with atrial fibrillation: an expanding clinical landscape
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Conclusion - Optimising antiplatelet strategies in acute coronary syndromes: where are we now?

Event : ESC Congress 2018

  • Session : Optimising antiplatelet strategies in acute coronary syndrome: where are we now?
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Discussion - Cardiovascular interventions in patients with atrial fibrillation: an expanding clinical landscape.

Event : Acute Cardiovascular Care 2018

  • Session : Cardiovascular interventions in patients with atrial fibrillation: an expanding clinical landscape
  • Speaker : M Lettino (Milano,IT), K Huber (Vienna,AT), P Vranckx (Hasselt,BE)
  • Sponsored by Daiichi Sankyo Europe GmbH

Moderated discussion - Spotlights on optimisation of guideline-supported reperfusion strategies for STEMI.

Event : ESC Congress 2018

  • Session : Spotlights on optimisation of guideline-supported reperfusion strategies for STEMI
  • Speaker : K Huber (Vienna,AT), R Welsh (Edmonton,CA), N Danchin (Montreuil,FR), JK French (Sydney,AU), AC De Camargo Carvalho (Moema-Sao Paulo,BR)
  • Sponsored by Boehringer Ingelheim

STEMI guideline updates: where are we now?

Event : ESC Congress 2018

  • Session : Spotlights on optimisation of guideline-supported reperfusion strategies for STEMI
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Boehringer Ingelheim

Thromboprophylaxis in acutely ill medical patients and in those with acute cardiovascular disease or undergoing cardiovascular procedures.

Event : Webinar 2018

  • Session : ACVC Webinars 2018
  • Speaker : A Cohen (London,GB), DC Gulba (Stuttgart,DE), K Huber (Vienna,AT)

Welcome and introduction - Optimising antiplatelet strategies in acute coronary syndromes: where are we now?

Event : ESC Congress 2018

  • Session : Optimising antiplatelet strategies in acute coronary syndrome: where are we now?
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Welcome to Acute Cardiovascular Care 2018.

Event : Acute Cardiovascular Care 2018

  • Session : Inaugural Session
  • Speaker : K Huber (Vienna,AT)

What the Consensus Document says...

Event : ESC Congress 2018

  • Session : 2018 Joint European Consensus Document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions
  • Speaker : K Huber (Vienna,AT)

Fast & immediate rule out strategy in patients with suspected ACS –strengths and limitations.

Event : Webinar 2017

  • Session : ACVC Webinars 2017
  • Speaker : E Giannitsis (Heidelberg,DE), K Huber (Vienna,AT), M Moeckel (Berlin,DE)

Non-Vitamin K Oral Anticoagulants (NOACs) in the “real world” – Opportunities for a differentiated therapy.

Event : Webinar 2017

  • Session : ACVC Webinars 2017
  • Speaker : K Huber (Vienna,AT), M Lettino (Milano,IT), JC Morais (Leiria,PT)

NSTEMI - The basic pillars of pharmacotherapy - Case.

Event : ESC Congress 2017

  • Session : Key messages from the most popular ESC webinars
  • Speaker : M Roffi (Geneva,CH), K Huber (Vienna,AT)

Summary and closing remarks - 40 years of percutaneous coronary intervention: optimising antiplatelet strategies in acute coronary syndrome.

Event : ESC Congress 2017

  • Session : 40 years of percutaneous coronary intervention: optimising antiplatelet strategies in acute coronary syndrome
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Welcome & introduction: 40 years of percutaneous coronary intervention.

Event : ESC Congress 2017

  • Session : 40 years of percutaneous coronary intervention: optimising antiplatelet strategies in acute coronary syndrome
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Acute coronary syndromes and acute cardiac care

Event : ESC Congress 2016

  • Session : ESC Congress Highlights
  • Speaker : K Huber (Vienna,AT)

Discussion – Summary and closing remarks: potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Event : ESC Congress 2016

  • Session : Potent P2Y12 receptor inhibition – What can we learn from clinical practice?
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Discussion.

Event : Acute Cardiovascular Care 2016

  • Session : Expanding insights into atrial fibrillation: non-vitamin K antagonist oral anticoagulants in patients undergoing (cardiovascular) interventions
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Future direction for research in platelet P2Y12 iinhibition in acute coronary syndromes

Event : ESC Congress 2016

  • Session : Rapid platelet P2Y12 iinhibition in acute coronary syndromes
  • Speaker : K Huber (Vienna,AT)

Future of anticoagulation in patients with atrial fibrillation undergoing cardiovascular intervention.

Event : Acute Cardiovascular Care 2016

  • Session : Expanding insights into atrial fibrillation: non-vitamin K antagonist oral anticoagulants in patients undergoing (cardiovascular) interventions
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

New tools to manage bleeding under NOACS.

Event : Acute Cardiovascular Care 2016

  • Session : Dilemmas in anti thrombotic therapy
  • Speaker : K Huber (Vienna,AT)
  • Joint session with the ESC Working Group on Thrombosis - This session is supported by an unrestricted educational grant from AstraZeneca

Optimal LDL reduction after acute coronary syndrome.

Event : Acute Cardiovascular Care 2016

  • Session : Secondary prevention after acute coronary syndromes
  • Speaker : K Huber (Vienna,AT)
  • Joint session with the European Association of Preventive Cardiology (EAPC)

The very elderly in the cath lab

Event : ESC Congress 2016

  • Session : Acute coronary syndromes in the very elderly
  • Speaker : K Huber (Vienna,AT)

Treasurer report.

Event : Acute Cardiovascular Care 2016

  • Session : ACCA General Assembly
  • Speaker : K Huber (Vienna,AT)

Triple therapy: individualise!

Event : Acute Cardiovascular Care 2016

  • Session : Update 2016: NSTEMI
  • Speaker : K Huber (Vienna,AT)

Welcome & introduction: Potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Event : ESC Congress 2016

  • Session : Potent P2Y12 receptor inhibition – What can we learn from clinical practice?
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

YIA Award: Acute Cardiovascular Care 2016.

Event : Acute Cardiovascular Care 2016

  • Session : Highlights from Acute Cardiovascular Care 2016 & Closing Ceremony
  • Speaker : K Huber (Vienna,AT)

Acute atrial fibrillation of more than 48 hours: who should be cardioverted? When? How?

Event : Acute Cardiovascular Care 2015

  • Session : Acute management of atrial fibrillation: how, when, why
  • Speaker : K Huber (Vienna,AT)

Acute coronary syndromes and acute cardiac care

Event : ESC Congress 2015

  • Session : ESC Congress Highlights
  • Speaker : K Huber (Vienna,AT)

Antithrombotic and antiplatelet therapy.

Event : Acute Cardiovascular Care 2015

  • Session : Update in NSTE-ACS
  • Speaker : K Huber (Vienna,AT)

Awards and closing : Acute Cardiovascular Care 2015.

Event : Acute Cardiovascular Care 2015

  • Session : Highlights from Acute Cardiovascular Care 2015 & Closing Ceremony
  • Speaker : K Huber (Vienna,AT)

Bivalirudin for ACS, end of story or bridge to the future?

Event : ESC Congress 2015

  • Session : Treatments for acute cardiac care: innovations or lost in translation?
  • Speaker : K Huber (Vienna,AT)

Choice of parenteral anticoagulation therapy.

Event : ESC Congress 2015

  • Session : Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome
  • Speaker : K Huber (Vienna,AT)

Future direction for research in anticoagulation therapy.

Event : ESC Congress 2015

  • Session : Oral anticoagulants still in the focus
  • Speaker : K Huber (Vienna,AT)

Patients with atrial fibrillation and acute coronary syndromes.

Event : Acute Cardiovascular Care 2015

  • Session : Acute coronary care in patients on chronic anticoagulation
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Treasurer report.

Event : Acute Cardiovascular Care 2015

  • Session : ACCA General Assembly
  • Speaker : K Huber (Vienna,AT)

Welcome and introduction - Acute coronary care in patients on chronic anticoagulation.

Event : Acute Cardiovascular Care 2015

  • Session : Acute coronary care in patients on chronic anticoagulation
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Daiichi Sankyo Europe GmbH

Welcome to Acute Cardiovascular Care 2015.

Event : Acute Cardiovascular Care 2015

  • Session : Inaugural Session
  • Speaker : K Huber (Vienna,AT)

ACCOAST: Discussant review

Event : ESC Congress 2014

  • Session : Clinical Trial Update Hot Line: Infarction, interventions and outcome
  • Speaker : K Huber (Vienna,AT)

EUROMAX trial and MULTIPRAC registry.

Event : ESC Congress 2014

  • Session : A year in acute cardiac care - news from the pre-hospital and intensive care settings
  • Speaker : K Huber (Vienna,AT)

Managing coronary stenting.

Event : ESC Congress 2014

  • Session : Warfarin or new anticoagulants in atrial fibrillation patients undergoing PCI
  • Speaker : K Huber (Vienna,AT)

Panel discussion: pharmaco-invasive vs. primary PCI.

Event : ESC Congress 2014

  • Session : STEMI 2014: aligning optimal care to time, place and person
  • Speaker : N Danchin (Montreuil,FR), PW Armstrong (Alberta,CA), F Van de Werf (Leuven,BE), K Huber (Vienna,AT), Y Lambert (Le Chesnay,FR), A Galyavich (Kazan,RU)
  • Sponsored by Boehringer Ingelheim

Should a regional STEMI centre only offer primary PCI?

Event : ESC Congress 2014

  • Session : STEMI 2014: aligning optimal care to time, place and person
  • Speaker : K Huber (Vienna,AT)
  • Sponsored by Boehringer Ingelheim

When to use GP IIb/IIIa receptor antagonists: pre-, peri- or post MI intervention? + case discussion..

Event : ESC Congress 2014

  • Session : 20 years clinical use of GP IIb/IIIa receptor antagonists: what have we learned and where to go?
  • Speaker : K Huber (Vienna,AT)
  • Organised by Leiden University Medical Centre / Course Director: Wouter Jukema / Supported by an unrestricted educational grant from Physicians’ Academy for Cardiovascular Education

Contra.

Event : ESC Congress 2013

  • Session : Every patient with non ST-elevation myocardial infarction should be treated with ticagrelor.
  • Speaker : K Huber (Vienna,AT)

Contra.

Event : ESC Congress 2013

  • Session : Every patient with non ST-elevation myocardial infarction should be treated with ticagrelor.
  • Speaker : K Huber (Vienna,AT)

Moving targets in interventional cardiology - Take home message & what do the guidelines say?

Event : ESC Congress 2013

  • Session : Moving targets in interventional cardiology
  • Speaker : K Huber (Vienna,AT)

The patient with heart failure, coronary anatomical lesions and no ischaemia: to revascularise or not revascularise.

Event : ESC Congress 2013

  • Session : Clinical challenges in cardiology: the best treatment alternative in difficult clinical case scenarios
  • Speaker : K Huber (Vienna,AT)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are